Unconventional immune-related phenomena observed using 18F-FDG PET/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies

Laurent Dercle (1, 2) , Fatima-Zohra Mokrane (2, 3) , Jean Marc Schiano de Colella (4) , Apasia Stamatoullas (5) , Franck Morschhauser (6) , Pauline Brice (7) , Hervé Ghesquières (8) , Olivier Casasnovas (9) , Aiping Chen (10) , Guillaume Manson (11, 12) , Roch Houot (11, 12)

1 UMR 1015 - Immunologie des tumeurs et immunothérapie
2 CUMC - Columbia University Medical Center
3 CHU Toulouse - Centre Hospitalier Universitaire de Toulouse
4 Institut Paoli-Calmettes
5 CLCC Henri Becquerel - Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen
6 GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365
7 Service d'Hémato-oncologie [CHU Saint-Louis]
8 Hôpital Edouard Herriot [CHU - HCL]
9 Service d'Hématologie Clinique (CHU de Dijon)
10 Nanjing Medical University
11 CHU Pontchaillou [Rennes]
12 MICMAC - Microenvironment, Cell Differentiation, Immunology and Cancer

The paradigm of response in Hodgkin lymphoma (HL) was developed in cytotoxic chemotherapies and its use as a reference model for immune-modulatory regimens, which restores the immune system's anti-tumor capacity, is questioned.

Keywords: Nivolumab; pembrolizumab; anti PD-1; Hodgkin lymphoma; 18F-FDG PET; PET/CT; computed tomography

Domains: Life Sciences [q-bio]; Cancer; Life Sciences [q-bio]; Human health and pathology; Hematology; Life Sciences [q-bio]; Immunology; Immunotherapy

Laurent Dercle, Fatima-Zohra Mokrane, Jean Marc Schiano de Colella, Apasia Stamatoullas, Franck Morschhauser, et al.. Unconventional immune-related phenomena observed using 18F-FDG PET/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46 (6), pp.1391-1392. ⟨10.1007/s00259-019-04310-x⟩. ⟨hal-02119287⟩